Seeking Alpha
05 Jun 2026, 03:37 UTC · 24w ago
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
Impact · against what's priced in
Edgewise Therapeutics receives a significant valuation boost from a $2.65 billion program sale and a cleared path toward a Phase 3 study for EDG-7500. The immediate cash infusion of $1.55 billion removes funding risk and provides a non-dilutive runway through potential commercialization.
- EWTX+0.80
No priced-in read yet
- In context
The sale of the muscular dystrophy program for $2.65 billion ($1.55 billion upfront) fundamentally alters the company's balance sheet and provides full funding for EDG-7500's development.
Read from the article alone





